Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 | $850K | $0.00 |
| Revenue growth | — | — | — | — | — | — | — | -100.0% |
| Operating income | — | -$34.1M | -$27.8M | -$81.9M | -$41.7M | -$50.4M | -$56.6M | -$72.8M |
| Operating margin | — | — | — | — | — | — | -6661.8% | — |
| Net income | — | -$34.7M | -$29.5M | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
| Net margin | — | — | — | — | — | — | -5808.8% | — |
| EPS (diluted) | — | -$5.19 | -$0.96 | -$1.31 | — | — | — | — |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$31.7M | -$26.8M | -$19.7M | -$34.1M | -$40.6M | -$44.9M | -$49.1M |
| Capital expenditures | — | $466K | $106K | $1.57M | $212K | $30.0K | $44.0K | $25.0K |
| Free cash flow | — | -$32.2M | -$26.9M | -$21.2M | -$34.3M | -$40.6M | -$44.9M | -$49.2M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $25.3M | $47.1M | $145M | $34.9M | $24.2M | $43.5M | $30.6M |
| Total assets | $25.00 | $30.4M | $51.9M | $154M | $200M | $157M | $140M | $220M |
| Total liabilities | $34.6K | $19.1M | $12.0M | $13.7M | $18.0M | $8.34M | $15.2M | $22.8M |
| Long-term debt | — | $9.29M | $1.87M | $0.00 | — | — | — | — |
| Shareholders' equity | -$84.8M | $11.3M | $39.9M | $140M | $182M | $149M | $125M | $197M |
| Retained earnings | -$35.1K | -$122M | -$151M | -$234M | -$273M | -$315M | -$365M | -$431M |
| Shares (wtd avg diluted) | 5.00M | 7.03M | 51.2M | 62.9M | 105M | 127M | 137M | 158M |
Every figure is extracted from Compass Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.